Overview

Entrée Study

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in non-small cell lung cancer (NSCLC) Participants

Objective

This study will evaluate new immunotherapy drug combinations compared with the current standard of care in the treatment of patients with advanced NSCLC who have progressed on prior anti-PD(L)1 and platinum-based combination chemotherapies.

Principal Investigator

Jason Comer, MD

Contact

Gina McBrayer, RN, MBA: 425.467.3986, eugenia.mcbrayer@overlakehospital.org

Tina Fortney, RN, CCRC: 425.688.5407, tina.fortney@overlakehospital.org

Find Locations & Directions

Find Locations & Directions

Contact us

Contact us

View Classes & Events

View Classes & Events